Vicarious Surgical Inc. Q1 FY2025 earnings call

• Vision: To revolutionize robotic surgery by overcoming limitations of existing approaches, aiming for clinical-stage status in 2025 with single-port surgical system. • Q1 Progress: Built first patient card and surgeon console for preclinical testing, began system integration; initial instrument sets completed production, with biocompatibility and sterility testing to begin. Preparing for first human cases, focusing on ventral hernia repair endpoint. • Partnerships: Announced strategic hospital system partnership with UMass Memorial Medical Center, adding to existing partnerships with leading healthcare institutions; collaboration focuses on optimizing robotic system integration, surgeon education, and best practices adoption.

• Ended Q1 2025 with ~$37 million in cash, cash equivalents, and short-term investments. • Q1 cash burn rate was approximately $12 million. • Full year 2025 cash burn is expected to be approximately $50 million, with commitment to disciplined capital allocation.

• Risks and uncertainties associated with the business are detailed in the company's Securities and Exchange Commission filings, including in the most recent form 10-K and form 10-Q.

Q: Concern about continued ability to fund operations given current cash balance and burn rate expectations.

A: Focus on disciplined spending to use cash effectively, evaluating financing options, having a supportive insider base, and planning to structure financing around upcoming milestones.

Q: Detail on technical dossier submission timeline for first patient testing and the role of hospital partners.

A: Expect to file technical dossier mid-2025 for first clinical patients, which includes safety and performance data; hospital partners are involved in optimizing perioperative practices, surgeon education, and system testing to drive best practices and adoption of the system.